JB Chemicals & Pharmaceuticals Limited - Asset Resilience Ratio

Latest as of March 2026: 14.87%

JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) has an Asset Resilience Ratio of 14.87% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check JB Chemicals & Pharmaceuticals Limited strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Rs7.39 Billion
≈ $79.91 Million USD Cash + Short-term Investments

Total Assets

Rs49.69 Billion
≈ $537.34 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2006–2026)

This chart shows how JB Chemicals & Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. See JB Chemicals & Pharmaceuticals Limited balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down JB Chemicals & Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs7.39 Billion 14.87%
Total Liquid Assets Rs7.39 Billion 14.87%

Asset Resilience Insights

  • Moderate Liquidity: JB Chemicals & Pharmaceuticals Limited has 14.87% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

JB Chemicals & Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio

Compare JB Chemicals & Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
SIMCERE PHARMAC. GRP LTD
F:S2P
Drug Manufacturers - Specialty & Generic 0.44%
Curaleaf Holdings Inc.
TO:CURA
Drug Manufacturers - Specialty & Generic 3.73%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Walvax BioTech
SHE:300142
Drug Manufacturers - Specialty & Generic 2.20%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for JB Chemicals & Pharmaceuticals Limited (2006–2026)

The table below shows the annual Asset Resilience Ratio data for JB Chemicals & Pharmaceuticals Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2026-03-31 14.87% Rs7.39 Billion
≈ $79.91 Million
Rs49.69 Billion
≈ $537.34 Million
+6.19pp
2025-03-31 8.68% Rs3.71 Billion
≈ $40.12 Million
Rs42.74 Billion
≈ $462.19 Million
-1.21pp
2024-03-31 9.89% Rs3.95 Billion
≈ $42.71 Million
Rs39.94 Billion
≈ $431.95 Million
+3.05pp
2023-03-31 6.83% Rs2.43 Billion
≈ $26.26 Million
Rs35.54 Billion
≈ $384.34 Million
+6.76pp
2022-03-31 0.07% Rs19.26 Million
≈ $208.31K
Rs26.07 Billion
≈ $281.98 Million
-29.79pp
2021-03-31 29.86% Rs6.68 Billion
≈ $72.28 Million
Rs22.38 Billion
≈ $242.04 Million
+9.86pp
2020-03-31 20.01% Rs3.63 Billion
≈ $39.24 Million
Rs18.14 Billion
≈ $196.13 Million
-0.98pp
2019-03-31 20.99% Rs3.76 Billion
≈ $40.65 Million
Rs17.91 Billion
≈ $193.69 Million
-1.10pp
2018-03-31 22.09% Rs3.90 Billion
≈ $42.16 Million
Rs17.65 Billion
≈ $190.87 Million
+8.65pp
2017-03-31 13.44% Rs2.25 Billion
≈ $24.33 Million
Rs16.74 Billion
≈ $181.04 Million
+0.90pp
2016-03-31 12.54% Rs1.95 Billion
≈ $21.12 Million
Rs15.57 Billion
≈ $168.43 Million
-24.84pp
2015-03-31 37.38% Rs5.56 Billion
≈ $60.12 Million
Rs14.87 Billion
≈ $160.84 Million
+0.58pp
2014-03-31 36.81% Rs4.97 Billion
≈ $53.78 Million
Rs13.51 Billion
≈ $146.11 Million
+6.20pp
2013-03-31 30.61% Rs3.98 Billion
≈ $43.04 Million
Rs13.00 Billion
≈ $140.61 Million
+5.65pp
2012-03-31 24.96% Rs2.99 Billion
≈ $32.33 Million
Rs11.98 Billion
≈ $129.54 Million
+18.14pp
2011-03-31 6.82% Rs681.15 Million
≈ $7.37 Million
Rs9.99 Billion
≈ $108.08 Million
-0.32pp
2010-03-31 7.13% Rs596.82 Million
≈ $6.45 Million
Rs8.37 Billion
≈ $90.51 Million
-0.64pp
2009-03-31 7.77% Rs579.99 Million
≈ $6.27 Million
Rs7.46 Billion
≈ $80.71 Million
-0.34pp
2008-03-31 8.11% Rs601.32 Million
≈ $6.50 Million
Rs7.41 Billion
≈ $80.17 Million
+2.87pp
2007-03-31 5.24% Rs373.14 Million
≈ $4.04 Million
Rs7.12 Billion
≈ $77.03 Million
-0.01pp
2006-03-31 5.25% Rs265.04 Million
≈ $2.87 Million
Rs5.05 Billion
≈ $54.64 Million
--
pp = percentage points

About JB Chemicals & Pharmaceuticals Limited

NSE:JBCHEPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$3.82 Billion
Rs352.99 Billion INR
Market Cap Rank
#4310 Global
#185 in India
Share Price
Rs2198.50
Change (1 day)
+0.13%
52-Week Range
Rs1614.40 - Rs2257.70
All Time High
Rs2257.70
About

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dos… Read more